ALT Quote, Financials, Valuation and Earnings

Actinium Pharmaceuticals, Inc. has a net margin of -380280% compared to Altimmune, Inc.'s net margin of -5701.11%. Altimmune, Inc.'s return on equity of -56.24% beat Actinium Pharmaceuticals, Inc.'s return on equity of -133.63%.

Altimmune, Inc. has a consensus price target of $17.38, signalling upside risk potential of 209.16%. On the other hand Actinium Pharmaceuticals, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 331.04%. Given that Actinium Pharmaceuticals, Inc. has higher upside potential than Altimmune, Inc., analysts believe Actinium Pharmaceuticals, Inc. is more attractive than Altimmune, Inc..

Altimmune, Inc. has a beta of 0.037, which suggesting that the stock is 96.298% less volatile than S&P 500. In comparison Actinium Pharmaceuticals, Inc. has a beta of -0.303, suggesting its less volatile than the S&P 500 by 130.258%.

Altimmune, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune, Inc. pays -- of its earnings as a dividend. Actinium Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Altimmune, Inc. quarterly revenues are $5K, which are smaller than Actinium Pharmaceuticals, Inc. quarterly revenues of $90K. Altimmune, Inc.'s net income of -$19M is lower than Actinium Pharmaceuticals, Inc.'s net income of -$5.1M. Notably, Altimmune, Inc.'s price-to-earnings ratio is -- while Actinium Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune, Inc. is 22,318.71x versus 402.08x for Actinium Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CorMedix, Inc. has a net margin of -380280% compared to Altimmune, Inc.'s net margin of 49.9%. Altimmune, Inc.'s return on equity of -56.24% beat CorMedix, Inc.'s return on equity of 95.25%.

Altimmune, Inc. has a consensus price target of $17.38, signalling upside risk potential of 209.16%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 91.46%. Given that Altimmune, Inc. has higher upside potential than CorMedix, Inc., analysts believe Altimmune, Inc. is more attractive than CorMedix, Inc..

Altimmune, Inc. has a beta of 0.037, which suggesting that the stock is 96.298% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.358, suggesting its more volatile than the S&P 500 by 35.753%.

Altimmune, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Altimmune, Inc. quarterly revenues are $5K, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Altimmune, Inc.'s net income of -$19M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Altimmune, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune, Inc. is 22,318.71x versus 2.61x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -380280% compared to Altimmune, Inc.'s net margin of 31.72%. Altimmune, Inc.'s return on equity of -56.24% beat Eli Lilly & Co.'s return on equity of 106.26%.

Altimmune, Inc. has a consensus price target of $17.38, signalling upside risk potential of 209.16%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,146.30 which suggests that it could grow by 9.33%. Given that Altimmune, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Altimmune, Inc. is more attractive than Eli Lilly & Co..

Altimmune, Inc. has a beta of 0.037, which suggesting that the stock is 96.298% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Altimmune, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Altimmune, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Altimmune, Inc. quarterly revenues are $5K, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Altimmune, Inc.'s net income of -$19M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Altimmune, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 51.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune, Inc. is 22,318.71x versus 15.91x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of -380280% compared to Altimmune, Inc.'s net margin of --. Altimmune, Inc.'s return on equity of -56.24% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.

Altimmune, Inc. has a consensus price target of $17.38, signalling upside risk potential of 209.16%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 221.59%. Given that Viking Therapeutics, Inc. has higher upside potential than Altimmune, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Altimmune, Inc..

Altimmune, Inc. has a beta of 0.037, which suggesting that the stock is 96.298% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.710, suggesting its less volatile than the S&P 500 by 28.988%.

Altimmune, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.

Altimmune, Inc. quarterly revenues are $5K, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Altimmune, Inc.'s net income of -$19M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Altimmune, Inc.'s price-to-earnings ratio is -- while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune, Inc. is 22,318.71x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.